ETF와이어ETF·펀드·패시브 투자, 매일 5분으로
etf1 min

a16z invests $75 million in Circle’s new Arc blockchain

Published: · Source: mk.co.kr

a16z invests $75 million in Circle’s new Arc blockchain
TL;DR: Venture capital firm a16z invested $75 million in ARC tokens for Circle’s new Arc blockchain, supporting enterprise stablecoin payment infrastructure.
Advertisement
11개 언어 자동 번역

Global venture capital firm a16z invested $75 million in ARC tokens for Circle’s new blockchain, Arc. Arc is described as a blockchain with enterprise control and privacy features, targeting stablecoin payments and settlement use cases. According to the original report, more than 200 allies, including Goldman Sachs and Visa, were cited, while settlement from payment to accounting within one second was presented as a core feature. The investment adds attention to whether stablecoins can challenge the territory of existing payment networks and fintech companies. Source: mk.co.kr

Advertisement
Get notifications

Partner picks

Relevant partner links for this story

A lightweight commerce block designed to add monetization without breaking reading flow.

This module may include affiliate links that earn a commission from qualifying purchases. ETF와이어

Sponsored
11개 언어 자동 번역
한 번 작성하면 11개 언어로 자동 노출
Advertisement
매일 5분 안에 핵심 뉴스

Related stories

KOSPI Jumps 81% Toward 8,000, While KOSDAQ’s 28% Rise Tests 3,000
etf1 min

KOSPI Jumps 81% Toward 8,000, While KOSDAQ’s 28% Rise Tests 3,000

As South Korean stocks keep setting record highs, the KOSPI has climbed 81% this year, fueling hopes for 8,000, while the KOSDAQ’s 28% gain leaves its 3,000 test in focus.

mk.co.kr
Hyosung Goodsprings to Debut High-Efficiency Pump Solution at HVAC KOREA 2026
etf1 min

Hyosung Goodsprings to Debut High-Efficiency Pump Solution at HVAC KOREA 2026

Hyosung Goodsprings will unveil a high-efficiency pump solution that cuts power use by 3.2% at HVAC KOREA 2026 from May 13 to 15, alongside solutions for data centers and building facilities.

mk.co.kr
Aprogen Osteoarthritis Drug AP209 Targets First Patient Dosing in Early August
etf1 min

Aprogen Osteoarthritis Drug AP209 Targets First Patient Dosing in Early August

Aprogen said it filed a clinical trial application for its osteoarthritis drug AP209 with South Korea’s Ministry of Food and Drug Safety in March and expects approval in late May or early June.

mk.co.kr